Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Hansoh Pharma
Biotech
GSK says 'stay tuned' for more ADC data as Hansoh posts 49% ORR
GSK may be happy with the latest Hansoh readouts, but the Big Pharma’s oncology R&D chief told Fierce to “stay tuned” for the company’s own data.
James Waldron
Oct 19, 2025 10:40am
Hansoh, Chugai ink separate and lucrative licensing agreements
Oct 17, 2025 11:04am
Regeneron pens $2B pact for Hansoh's potential rival to Zepbound
Jun 2, 2025 8:20am
Silence slows zerlasiran, as Hansoh leaves $1.3B biobucks collab
Feb 27, 2025 8:51am
Merck pays $112M upfront for Hansoh's preclinical GLP-1
Dec 18, 2024 7:44am
Hansoh signs $690M ADC pact with fellow Chinese biotech Biotheus
Mar 15, 2024 8:35am
